FXR Agonist PBC Studies

CME

Selected FXR Agonist PBC Studies: Conference Coverage of AASLD

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: December 20, 2023

Expiration: December 19, 2024

Kris V. Kowdley
Kris V. Kowdley, MD, FAASLD, FACP, FACG

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Your colleague asks about data to support using obeticholic acid (OCA) plus bezafibrate (BZF) added to ursodeoxycholic acid (UDCA) for people with primary biliary cholangitis (PBC) who were unable to achieve an adequate response to UDCA treatment. Based on 2 recent clinical trials, what would you say? Compared with placebo, addition of OCA plus BZF to UDCA therapy was associated with:

2.

I am familiar with PBC data from the AASLD 2023 conference, and I plan to translate these data into current or future management strategies.